chartexchange

Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

Business Wire | Nov 4, 2026 4:05 PM EST

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “In October, we showed for the first time that robust and durable HIF-2

Read original article